

Reagan Haney

Herz Global Impact Award Ph.D. Candidate, Biochemistry and Molecular Biology Third Year ARCS Scholar



Discovering the Mechanism of Action of a Novel Antimalarial

Malaria is a devastating disease that caused approximately 608,000 deaths in 2022 worldwide. Cases of malaria have increased from previous years because of quick development of resistance to frontline antimalarials such as chloroquine and artemisinin. Due to rising resistance, there is an urgent need to discover and develop new drugs that engage new targets in the malaria parasite. This research focuses on a novel antimalarial called PRC1584.


Malaria and the novel antimalarial PRC1584



Rapid emergence and spread of resistance to artemisinin's threaten the worldwide malaria control and eradication strategies




PRC1584 meets all the requirements needed to become an early lead antimalarial candidate



Discover the mechanism of action and molecular target(s) of PRC1584

How does it work?

Malaria Life Cycle




Early Lead Criteria for Antimalarials Global Health Innovative Technology (GHIT) Fund and PRC1584 Medicines for Malaria Venture (MMV) devised the following disease-specific criteria for early leads for malaria. Image » Treatment P. berghei EC₅₀ <100 nM for sensitive and multidrug-resistant strains of plasmodium spp. >100 in mammalian cells Selectivity Day 5 (2T) Day 7 (4T) Index When administered orally in blood stages of In vivo efficacy Clearance at a dose that eradicates 90% of the target (<50 mg/kg) (four doses over 4 days) Irresistible Unable to generate resistance

Artemisinin Induced Quiescence


Quiescence is the altered ring stage development in artemisininresistant P. falciparum in which ring stages persist for extended periods of development in the absence of drug.



8-hour exposure to artemisinin



Does PRC1584 kill DHA-induced quiescent ring stage?



Short exposure to PRC1584 kills both proliferating and **DHA-induced quiescent ring** stages.

Chemoproteomic Approach DBCO- Magnet Linker attached Cell Lysis & Protein Extraction In vitro **Cross Linking** PRC1584 + Probe Selection of candidate proteins LC- MS/MS

OUNDATION